Hemodynamic Profile of the Cardiotonic Agent Pimobendan

Meel, J. C. A. Van; Diederen, W.

doi:10.1097/00005344-198900142-00002

Cited by 26 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maximal effects, which were significantly different to values from dogs in the control group, were observed between 3 and 4 h following treatment. These parameters relate to enhanced left ventricular systolic function and are consistent with findings of prior studies in dogs in which invasive monitoring methods were used (Von Meel, 1985;Pouleur et al, 1988Pouleur et al, , 1989Van Meel & Diederen, 1989;Ohte et al, 1997;FDA-CVM, 2007).…”

Section: Discussionsupporting

confidence: 85%

“…The maximal effects observed in this study occurred slightly later (3-4 h) than in prior invasive studies evaluating systolic function after oral doses (1.5-2 h) (Von Meel, 1985;Van Meel & Diederen, 1989). This is most likely attributable to the use of higher dosages (0.5-1 mg/kg) in prior studies as a shorter time to maximal effect for higher dosages has been previously reported in dogs (FDA-CVM, 2007) and in humans (Walter et al, 1988).…”

Section: Discussionmentioning

confidence: 45%

See 1 more Smart Citation

Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs

Yata

McLachlan

Foster

et al. 2015

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Pimobendan is an inodilator used in the treatment of canine congestive heart failure (CHF). The aim of this study was to investigate the pharmacokinetics and cardiovascular effects of a nonaqueous oral solution of pimobendan using a single-dose, operator-blinded, parallel-dose study design. Eight healthy dogs were divided into two treatment groups consisting of water (negative control) and pimobendan solution. Plasma samples and noninvasive measures of cardiovascular function were obtained over a 24-h period following dosing. Pimobendan and its active metabolite were quantified using an ultra-high-performance liquid chromatography-mass spectrometer (UHPLC-MS) assay. The oral pimobendan solution was rapidly absorbed [time taken to reach maximum concentration (Tmax ) 1.1 h] and readily converted to the active metabolite (metabolite Tmax 1.3 h). The elimination half-life was short for both pimobendan and its active metabolite (0.9 and 1.6 h, respectively). Maximal cardiovascular effects occurred at 2-4 h after a single oral dose, with measurable effects occurring primarily in echocardiographic indices of systolic function. Significant effects persisted for <8 h. The pimobendan nonaqueous oral solution was well tolerated by study dogs.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 45%

Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs

Yata

McLachlan

Foster

et al. 2015

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…administration of pimobendan in the current study indicates a decrease in preload. This is consistent with data in other species, demonstrating that pimobendan induces arterial and venous dilation [4,5,26,27].…”

Section: Discussionsupporting

confidence: 92%

“…It is considered a nonsympathomimetic, nonglycoside inotropic agent that exerts its action mainly via calcium sensitisation through increased affinity of cardiac troponin C for calcium [1,2]. In addition, by means of phosphodiesterase III inhibition, pimobendan further augments the myocardial inotropic state [3] while inducing arterial and venous dilation [4,5]. These effects are particularly attractive for the treatment of the failing heartincreased contractility and afterload reduction favourably affect cardiac output and there are clear advantages of preload reduction in diminishing cardiogenic pulmonary oedema, if present.…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular effects of pimobendan in healthy mature horses

Afonso

Giguère

Rapoport

et al. 2015

Equine Veterinary Journal

View full text Add to dashboard Cite

show abstract

“…The inodilator pimobendan is a phosphodiesterase (PDE) III inhibitor with positive inotropic activity (via increased sensitivity of the contractile apparatus to calcium), vasodilatory (via phosphodiesterase inhibition), and some additional PDE V inhibitory effects. [4][5][6] As a result, possible effects of pimobendan include increasing cardiac output (CO) and myocardial contractility, and decreasing preload and afterload. Pimobendan extends survival time and improves the quality of life in chronic heart failure (CHF) patients with MVD and dilated cardiomyopathy.…”

mentioning

confidence: 99%

The Effect of Pimobendan on Left Atrial Pressure in Dogs with Mitral Valve Regurgitation

Suzuki

Fukushima

Ishikawa

et al. 2011

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: The effects of pimobendan on left atrial pressure (LAP) in dogs with mitral valve disease (MR) have not been documented in a quantitative manner.Objective: The objective was to document and study the short-term effects of pimobendan on LAP and echocardiographic parameters in MR dogs.Animals: Eight healthy Beagle dogs weighing 10.0-14.7 kg (3 males and 5 females; aged 2 years) were used. Methods: Experimental, cross-over, and interventional study. Dogs with surgically induced MR received pimobendan at either 0.25 mg/kg or 0.50 mg/kg PO q12h for 7 days and then, after a 7-day wash-out period, the other dosage. LAP was measured for 30 minutes at baseline and again on days 1, 2, 4, and 7 of pimobendan administration.Results: Mean LAP was significantly decreased after the administration of 0.25 mg/kg (15.81 ± 5.44 mmHg to 12.67 ± 5.71 mmHg, P < .001) and 0.50 mg/kg (15.76 ± 5.45 mmHg to 10.77 ± 5.23 mmHg, P < .001). Also, the 0.50 mg/ kg group led to a significantly lower LAP (P < .01) compared with the 0.25 mg/kg group. Significant reduction was seen for the first time 4 days after the administration of 0.25 mg/kg and a day after the administration of 0.50 mg/kg.Conclusions and Clinical Importance: Pimobendan decreased LAP in a dose-dependent manner in dogs with acute MR caused by experimental chordal rupture. This study did not evaluate adverse effects of high-dose pimobendan, and additional studies in clinical patients are warranted.

show abstract

Hemodynamic Profile of the Cardiotonic Agent Pimobendan

Cited by 26 publications

References 0 publications

Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs

Pharmacokinetics and cardiovascular effects following a single oral administration of a nonaqueous pimobendan solution in healthy dogs

Cardiovascular effects of pimobendan in healthy mature horses

The Effect of Pimobendan on Left Atrial Pressure in Dogs with Mitral Valve Regurgitation

Contact Info

Product

Resources

About